MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

79.41 -5.05 (-5.98%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
News headline image
2 cash-producing stocks to research further and 1 facing challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
2 profitable stocks on our buy list and 1 we avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat... 
Via StockStory
News headline image
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
From DexCom, Inc.
Via Business Wire
DexCom (NASDAQ:DXCM): Affordable Growth at a Reasonable Valuation ↗
Via Chartmill
DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup ↗
Via Chartmill
News headline image
3 quality compounders with promising prospects
A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits... 
Via StockStory
S&P 500 Unusual Volume Movers for Oct. 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory
Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 11.2% year on year to $1.34 billio... 
Via StockStory
News headline image
Dexcom (DXCM) Q3 2026 Earnings Call Transcript ↗
Record patient starts and type 2 diabetes share gains fuel 11% revenue growth. 
Via The Motley Fool
Topics Earnings
News headline image
What DexCom (DXCM) Said on Its Q3 Earnings Call ↗
DexCom (NASDAQ:DXCM) reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing... 
Via MarketBeat
Topics Earnings Initial Public Offering
News headline image
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution ↗
These aren’t top AI stocks, but the technology is helping improve their businesses. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
DexCom (NASDAQ:DXCM) beats Q3 2026 sales expectations
Medical device company DexCom (NASDAQ:DXCM) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 11.2% year on year to $1.34 ... 
Via StockStory
News headline image
Dexcom Reports Third Quarter 2026 Financial Results
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
From DexCom, Inc.
Via Business Wire
News headline image
What to expect from DexCom’s (DXCM) Q3 earnings
Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what investors should know. DexCom beat analysts’ ... 
Via StockStory
S&P 500 Unusual Volume Movers in Today's Session ↗
Via Chartmill
Topics Stocks
S&P 500 Top Movers: Oct. 21, 2026 US Session ↗
Via Chartmill
Topics Stocks
S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers ↗
Via Chartmill
Topics Stocks
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
From DexCom, Inc.
Via Business Wire
News headline image
Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
From DexCom, Inc.
Via Business Wire
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
From DexCom, Inc.
Via Business Wire
News headline image
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗
Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth. 
Via MarketBeat
Topics Initial Public Offering
News headline image
2 Nasdaq 100 Stocks for Long-Term Investors and 1 We Turn Down
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story